Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

INJECTABL-II: Dose Finding, Efficacy and Immunological Response of a Novel Immuno-Adjuvant (IP-001) Following Microwave Ablation or Irreversible Electroporation for Colorectal Liver Metastases.

NCT06630624 is registered in ClinicalTrials.gov with M.R. Meijerink as lead sponsor.

NCT NCT06630624
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06630624 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
INJECTABL-II: Dose Finding, Efficacy and Immunological Response of a Novel Immuno-Adjuvant (IP-001) Following Microwave Ablation or Irreversible Electroporation for Colorectal Liver Metastases.
Lead sponsor
M.R. Meijerink
Phase
Phase 1/2
Overall status
Recruiting
Start date
July 10, 2024
Completion date
August 1, 2031
Enrollment
120 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer, liver metastases, liver metastasis colon cancer